TGTX Tg Therapeutics Earnings and EPS analysis

Relative Growth: Rel. Growth: 96

Relative Strength: Rel. Strength: 76

Relative Valuation: Rel. Valuation: 74

Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $3.22

Last Report Period Date: Mar 31, 2026

According to the most recent financial data from March 2026, the current EPS (TTM) is $3.22. Tg Therapeutics's EPS for 2025 came in at $3.1, marking an increase from $0.16 in 2024. For the quarterly period ending on Mar 31, 2026, TGTX's EPS was $0.14.

TGTX earnings history

Historical annual and quarterly earnings per share (EPS) data for Tg Therapeutics

EPS (TTM)

$3.22

EPS Growth YoY (Quarterly)

366.7%

EPS (Quarterly)

$0.14

EPS Growth (Quarterly)

-30%

Tg Therapeutics had an annual EPS of $3.1, marking an increase of 1,837.5% from $0.16 in 2024. The quarterly EPS for the period ending Mar 31, 2026, was $0.14, marking a 366.7% increase from the same quarter last year. TGTX's TTM EPS stands at $3.22 as of March 2026. Tg Therapeutics's EPS for 2024 stood at $0.16, a 77.8% increase from 2023.

TGTX earnings chart

TGTX EPS growth history

Earnings per share growth rates over time

EPS Growth YoY (Quarterly)

366.7%

EPS growth YoY

1,837.5%

EPS growth 3Y avg

N/A

EPS growth 5Y avg

N/A

Over the last 12 months, Tg Therapeutics has registered an EPS growth of 366.7% (YoY, quarterly).

TGTX Earnings Waterfall

Breakdown of revenue, profit and net income for Tg Therapeutics

TGTX Earnings vs Peers

What are the earnings of TGTX compared to its peers

Stock name	Price to Earnings	EPS grwoth 1Y	EPS grwoth 3Y	EPS grwoth 5Y
TGTX Tg Therapeutics Inc	12.59	1,837.5%	N/A	N/A
ALKS Alkermes plc	46.63	-33.8%	N/A	N/A
NERV Minerva Neurosciences Inc	N/A	-18,347.4%	N/A	N/A

All data is based on quarterly TTM periods, unless otherwise specified.